Antibiotics

Nabriva Therapeutics plans to file a New Drug Application with the FDA in the fourth quarter of 2018.

Bruce A. Mueller, PharmD, shares some of the pharmacokinetic alterations that occur in patients who are in acute kidney failure in the intensive care unit.

Comparing 2 commonly prescribed treatments for urinary tract infections, an international team of researchers discovers that 1 is clearly superior.

Kenneth P. Klinker, PharmD, and Jason M. Pogue, PharmD, share some strategies to address beta-lactam dosing issues that they employ at their institutions.

Edward J. Septimus, MD, explains how smaller hospitals can overcome the challenges that come with having fewer resources to implement a robust antibiotic stewardship program.

The drug met its primary endpoint of noninferiority to vancomycin at both 48 to 72 hours after drug initiation and test of cure.

Jason M. Pogue, PharmD, discusses the challenges clinicians face when dosing beta-lactams based on the current guidelines.

In case you missed them, we’ve compiled a list of the latest recalls posted this week.

Bruce A. Mueller, PharmD, shares how clinicians in the inpatient setting can quantify acute kidney injury in adults on antibiotics.

A new study shows the benefits of widespread antibiotic distribution, but what about concerns about encouraging antibiotic resistance?

A study shows that pharmacist-driven education and encouragement of antibiotic self-stewardship can decrease the duration of therapy for broad-spectrum antibiotics.

A new literature review offers a summary of the latest research into uncomplicated bacteremia.

New software unveiled last month suggests hospitals could make patient-specific predictions of antibiotic susceptibility.

The rise in antibiotic resistance has led experts to focus on how to appropriately manage and regulate shared-use antibiotics in humans and animals.

Julia E. Szymczak, PhD, shares the results of her study which revealed that fear drives some clinicians to prescribe inappropriately.

This emotional drive carried throughout the continuum of the prescribing pathway, from initial prescription to stopping or de-escalating antibiotics.

Investigational beta-lacatamase inhibitor IMI/REL demonstrates a favorable overall response against certain imipenem-non-susceptible bacterial infections.

Researchers present positive new data from multiple studies of VIBATIV at the 2018 ECCMID conference in Madrid, Spain.

Expert panelists in the field of infectious diseases discuss the growing threat of antimicrobial resistance.

According to recent research from Johns Hopkins Medicine, when it comes to making choices on appropriate antibiotic prescribing, outpatient providers are making the decision based on patient demand, not necessarily on what's actually appropriate for the condition.

Mike Kohut, PhD shares the results of his research that reveals providers are writing prescriptions for infections based largely on patient demand and not guideline recommendations.

In the SHEA Spring 2018 Opening Plenary, Zintars Beldavs stresses the importance of communication and collaboration in the fight against antimicrobial resistance.

Contagion® will be covering the conference, and so, keep a look out for session coverage as well as interviews with some of the key presenters.

One dose of microbiota-based therapy proved more effective than 2 at wiping out recurrent C. difficile infection.

Study finds antibiotic use alters native gut bacteria that normally compete with C. diff for nutrients.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

In a new international study, a team of European authors says that antibiotic use for preventative purposes is too high in pediatric hospitals, prompting a call for better antibiotic stewardship efforts.

The first case of gonorrhea resistant to available first-line antibiotics has been reported in the United Kingdom.

Coordinated efforts with health departments at the local and state levels are protecting individuals by stopping the spread of new and unusual types of antibiotic resistance throughout the United States.

Here’s what needs to be addressed in order to make real progress in the fight against antimicrobial resistance, according to Dr. Ramanan Laxminarayan, PhD, Center for Disease Dynamics, Economics, & Policy.